NCT01864018 - Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2013

Primary Completion Date

April 30, 2021

Study Completion Date

September 9, 2023

Conditions

AmyloidosisPlasma Cell Myeloma

Interventions

DRUG

Cyclophosphamide

Given PO

DRUG

Dexamethasone

Given PO

DRUG

Ixazomib Citrate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (2)

Mayo Clinic, Rochester

Mayo Clinic in Arizona, Scottsdale